Skip to content

Evaluation of anti-obesity effect of test food

Evaluation of anti-obesity effect of test food - Evaluation of anti-obesity effect of test food

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000030834
Enrollment
15
Registered
2018-07-10
Start date
2018-01-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Duration: 12 weeks Test foods: Seaweed (Ascophyllum nodosum) extract-containing tablet One tablet per day

Sponsors

MEDIPHARMA CORP.
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Men of Japanese 2) 25<=BMI<30

Exclusion criteria

Exclusion criteria: 1) Currently under the treatment with medication, diet or exercise therapy. 2) At least one previous medical history of hepatic disorder, renal disorder, endocrine system diseases, cardiovascular disorder, gastrointestinal disorder, pulmonary disease, hematological disorder, or metabolic disorder. 3) Currently taking functional foods or supplements which would affect blood glucose level or body fat percentage. 4) Those who are allergic to medicines or foods. 5) Those who working irregularly such as working on night shift. 6) Enrolled into other clinical trials within the last 3 months before agreeing to participate in this trial. 7) Others considered as inappropriate for the study by the physician.

Design outcomes

Primary

MeasureTime frame
1) Body weight 2) BMI 3) Abdominal circumference 4) Abdominal CT 5) Body fat percentage (0, 12 week)

Secondary

MeasureTime frame
1) Hematological tests 2) Blood biochemistry tests (0, 12 week)

Countries

Japan

Contacts

Public ContactKana Arai

MEDIPHARMA CORP. Clinical development support division, Site administration office

arai@medipharma.co.jp03-5733-0441

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026